Avalanche hits the brakes on its gene therapy program after a Phase II misstep

Damian Garde

Biotechnologies, months removed from a costly II dud, is calling off plans for further study of its lead candidate, heading back to the lab to regroup before trying another clinical trial.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS